Yanjum Ma, MD
Medical Oncology · Murfreesboro, TNNPI 1598973273
Payments from drug & device makers
Across 103 payments — averaging $181.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$4K
- Deciphera Pharmaceuticals Inc.$3K
- AstraZeneca$3K
- Stemline Therapeutics Inc.$2K
- Bayer$2K
- Johnson & Johnson$2K
- plus $2K from 27 others
Across 3 payments — averaging $476.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1K
What the payments were for
- Consulting fees$13,20171%
- Speaking & faculty fees$3,22517%
- Travel & lodging$991%
- Food & beverage$2,13111%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 1 | $4,050 |
| Deciphera Pharmaceuticals Inc. | 9 | $3,487 |
| AstraZeneca(2 entities) | 8 | $2,875 |
| Stemline Therapeutics Inc. | 1 | $2,480 |
| Bayer | 5 | $2,318 |
| Johnson & Johnson | 4 | $1,544 |
| Beigene, Ltd. | 1 | $450 |
| Merck | 15 | $259 |
| Astellas Pharma US Inc | 11 | $196 |
| Bristol Myers Squibb | 8 | $191 |
| Novartis | 6 | $109 |
| Adaptive Biotechnologies Corporation | 1 | $97 |
| AbbVie | 4 | $76 |
| Pfizer | 5 | $73 |
| AVEO Pharmaceuticals, Inc. | 2 | $55 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| GSK | 2 | $38 |
| Amgen | 2 | $34 |
| Ipsen Biopharmaceuticals, Inc | 1 | $32 |
| Tesaro, Inc. | 1 | $31 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $23 |
| Servier Pharmaceuticals LLC | 1 | $21 |
| Eisai Inc. | 1 | $19 |
| Pharmacosmos Therapeutics Inc. | 1 | $18 |
| Seagen Inc. | 1 | $17 |
| Beone Medicines USA, Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
| Boston Scientific | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Kyowa Kirin, Inc. | 1 | $13 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,667 in reported general payments places this provider in the 50th percentile of 101 medical oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 153 | $2,401,478 |
| VerzenioAbemaciclib | 50 | $834,939 |
| ImbruvicaIbrutinib | 38 | $593,070 |
| CalquenceAcalabrutinib Maleate | 41 | $579,697 |
| JakafiRuxolitinib Phosphate | 28 | $471,279 |
| IbrancePalbociclib | 31 | $466,281 |
| TagrissoOsimertinib Mesylate | 22 | $338,954 |
| NubeqaDarolutamide | 24 | $316,850 |
| XtandiEnzalutamide | 20 | $281,469 |
| LenvimaLenvatinib Mesylate | 11 | $250,797 |
| TalzennaTalazoparib Tosylate | 13 | $237,474 |
| SprycelDasatinib | 11 | $195,294 |
| BrukinsaZanubrutinib | 15 | $192,145 |
| VenclextaVenetoclax | 21 | $171,953 |
| GilotrifAfatinib Dimaleate | 13 | $151,800 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $191 | $2,401,478153 claims |
| AstraZenecaCalquence, Tagrisso | $2,875 | $918,65063 claims |
| Lilly USA, LLCVerzenio | $4,050 | $834,93950 claims |
| PfizerIbrance, Talzenna, Eliquis | $73 | $785,629159 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $23 | $593,07038 claims |
| BayerNubeqa | $2,318 | $316,85024 claims |
| Astellas Pharma US IncXtandi | $196 | $281,46920 claims |
| NovartisPromacta, Kisqali | $109 | $259,78227 claims |
| Eisai Inc.Lenvima | $19 | $250,79711 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $45 | $195,29411 claims |
| AbbVieVenclexta | $76 | $171,95321 claims |
| Johnson & JohnsonXarelto | $1,544 | $21,96529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 101 medical oncology providers in Tennessee.
Other medical oncology in Murfreesboro
- Johann BrandesMurfreesboro$165K
- Victor GianMurfreesboro$48K
- Melissa JohnsonNashville$46M
- David SpigelNashville$29.7M
- Gregory VidalGermantown$12.5M
- Howard BurrisNashville$12.2M
- Ingrid MayerNashville$6.3M
- Daniel VaenaGermantown$5M
- Ari VanderwaldeGermantown$4.9M
- Gina VaccaroCookeville$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.